`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 1 -
`
`EPIGENETIC CHANGE IN SELECTED GENES AND CANCER
`
`FIELD OF THE INVENTION
`
`The present invention relates to methods and kits for
`
`5
`
`identifying and diagnosing cancer which include detecting an
`
`epigenetic change, such as a change in the methylation
`
`status, or the expression levels, or a combination thereof
`
`of any one or more of a number of genes. Also described are
`
`pharmacogenetic methods for determining suitable treatment
`
`10
`
`regimens for cancer and methods for treating cancer
`
`patients, based around selection of the patients according
`
`to the methods of the invention. The present invention is
`
`also concerned with improved methods of collecting,
`
`processing and analyzing samples, in particular body fluid
`
`15
`
`samples. More particularly, the invention relates to
`
`methods for identifying epigenetic changes in body fluid
`
`samples. These methods may be useful in diagnosing, staging
`
`or otherwise characterizing various diseases. The invention
`
`also relates to methods for identifying, diagnosing, staging
`
`20
`
`or otherwise characterizing cancers, in particular
`
`gastrointestinal cancers such as colorectal cancers, gastric
`
`cancers and oesophageal cancers. The methods of the
`
`invention relate, inter alia, to isolating and analyzing the
`
`human DNA component from faecal samples and blood-based
`
`25
`
`samples.
`
`BACKGROUND OF THE INVENTION
`
`In their earliest stages most cancers are clinically silent.
`
`Patient diagnosis typically involves invasive procedures
`
`30
`
`that frequently lack sensitivity and accuracy. Highly
`
`reliable, non-invasive screening methods would permit easier
`
`patient screening, diagnosis and prognostic evaluation.
`
`Geneoscopy Exhibit 1073, Page 2
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 2 -
`
`Tumour derived markers are biological substances that are
`
`usually produced by malignant tumours. Ideally a tumour
`
`derived marker should be tumour-specific, provide an
`
`5
`
`indication of tumour burden and should be produced in
`
`sufficient amounts to allow the detection of minimal
`
`disease. Most tumour derived markers used in clinical
`
`practice are tumour antigens, enzymes, hormones, receptors
`
`and growth factors that are detected by biochemical assays.
`
`10
`
`The detection of DNA alterations such as mutations,
`
`deletions and epigenetic modifications (Baylin et al., 2000)
`
`provide another means for identifying cancers.
`
`An epigenetic modification can be described as a stable
`
`15
`
`alteration in gene expression potential that takes place
`
`during development and cell proliferation, mediated by
`
`mechanisms other than alterations in the primary nucleotide
`
`sequence of a gene.
`
`It is now general knowledge that both
`
`genetic and epigenetic alterations can lead to gene
`
`20
`
`silencing and cellular dysfunction. Synergy between these
`
`two processes drives tumor progression and malignancy.
`
`Three related mechanisms that cause alteration in gene
`
`expression are recognised: DNA methylation, histone code
`
`changes and RNA interference.
`
`25
`
`DNA hypermethylation is an epigenetic modification whereby
`
`the gene activity is controlled by adding methyl groups
`
`(CH 3 ) to specific cytosines of the DNA. In particular,
`methylation occurs in the cytosine of the CpG dinucleotides
`
`30
`
`(CpG islands) which are concentrated in the promoter regions
`
`and intrans in human genes (P.A. Jones et al., 2002; P.W.
`
`Laird et al., 2003). Methylation is associated with gene
`
`Geneoscopy Exhibit 1073, Page 3
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 3 -
`
`silencing. DNA hypermethylation is found to be involved in
`
`a variety of cancers including lung, breast, ovarian,
`
`kidney, cervical, prostate and also colorectal cancer.
`
`Methylation patterns of DNA from cancer cells are
`
`5
`
`significantly different from those of normal cells.
`
`Therefore, detection of methylation patterns in
`
`appropriately selected genes of cancer cells can lead to
`
`discrimination of cancer cells from normal cells, thereby
`
`providing an approach to early detection of cancer.
`
`10
`
`DNA tumour markers, in particular DNA methylation markers,
`
`offer certain advantages when compared to other biochemical
`
`markers. An important advantage is that DNA alterations
`
`often precede apparent malignant changes and thus may be of
`
`15
`
`use in early diagnosis of cancer. Since DNA is much more
`
`stable and, unlike protein, can be amplified by powerful
`
`amplification-based techniques for increased sensitivity, it
`
`offers applicability for situations where sensitive
`
`detection is necessary, such as when tumour DNA is scarce or
`
`20 diluted by an excess of normal DNA (Sidransky et al.,1997).
`
`Bodily fluids provide a cost-effective and early non(cid:173)
`
`invasive procedure for cancer detection. In this context,
`
`faecal-based cancer testing has been one area of
`
`investigation.
`
`25
`
`Human colorectal cancer has provided a good model for
`
`investigating whether DNA cancer markers can be adopted as
`
`an optimal faecal-based diagnostic screening test. Central
`
`to faecal-based colorectal cancer testing has been the
`
`30
`
`identification of specific and sensitive cancer derived
`
`markers.
`
`Geneoscopy Exhibit 1073, Page 4
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`-
`
`4 -
`
`The N-Myc downstream-regulated gene (NDRG) family comprises
`
`four family members: NDRGl
`
`(NDRG-family member 1), NDRG2
`
`(NDRG-family member 2), NDRG3
`
`(NDRG-family member 3) and
`
`NDRG4
`
`(NDRG-family member 4). The human NDRGl and NDRG3
`
`5
`
`belong to one subfamily, and NDRG2 and NDRG4 to another. At
`
`amino acid (aa) level, the four members share 53-65%
`
`identity. The four proteins contain an alpha/beta hydrolase
`
`fold as in human lysosomal acid lipase but are suggested to
`
`display different specific functions in distinct tissues.
`
`10
`
`NDRGl codes for a cytoplasmic protein believed to be
`
`involved in stress responses, hormone responses, cell
`
`growth, and cell differentiation. NDRGl has been
`
`demonstrated to be upregulated during cell differentiation,
`
`15
`
`repressed by N-myc and c-myc in embryonic cells, and
`
`suppressed in several tumor cells (Qu X et al.,2002; Guan et
`
`al.,2000).
`
`NDRG3 is believed to play a role in spermatogenesis since it
`
`20
`
`is highly expressed in testis, prostate and ovary (Zhao Wet
`
`al., 2001). Its involvement in brain cancer development has
`
`also been suggested (Qu X et al. 2002).
`
`NDRG2 codes for a cytoplasmic protein that seems to be
`
`25
`
`involved in neurite outgrowth and in glioblastoma
`
`carcinogenesis (Deng Yet al., 2003).
`
`It is upregulated at
`
`both the RNA and protein levels in Alzheimer's disease
`
`brains (Mitchelmore C et al., 2004), and has also been
`
`suggested to play an important role in the development of
`
`30 brain cancer (Qu X et al. 2002), pancreatic cancer and liver
`
`cancer (Hu XL et al., 2004).
`
`Geneoscopy Exhibit 1073, Page 5
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`-
`
`5 -
`
`The NDRG4 cytoplasmic protein is involved in the regulation
`
`of mitogenic signalling in vascular smooth muscles cells
`
`(Nishimoto Set al.). The NDRG4 gene contains 17 exons, and
`
`several alternatively spliced transcript variants of this
`
`5
`
`gene have been described. NDRG4 may also be involved in
`
`brain cancer development (Qu X et al. 2002).
`
`Suppressed expression of NDRG-family genes has been
`
`demonstrated in a number of tumours (Qu X et al. 2002) and
`
`10
`
`the involvement of DNA promoter hypermethylation is limited
`
`to the reporting of NDRG2 methylation in brain tumors (Lusis
`
`et al., 2005).
`
`Initially, faecal-based DNA assays investigated the
`
`15 usefulness of specific point mutations markers for detecting
`
`colorectal cancer. Later, the DNA integrity in faecal
`
`samples proved to be a useful marker (Boynton et al., 2003).
`
`Finally, faecal testing based on DNA alterations gradually
`
`evolved into the development of a multi-target DNA assay
`
`20
`
`using specific point mutation markers, a microsatellite
`
`instability marker and a marker for DNA integrity.
`
`Recently, the potential of faecal DNA testing targeting
`
`epigenetic alterations has been investigated (Muller et al.,
`
`2004, Chen et al., 2005) and ha~ been added to the multi-
`
`25
`
`target DNA assay. Genes having an altered methylation
`
`status traceable in faecal DNA from colon cancer patients
`
`versus control samples from healthy subjects have been
`
`discovered (Belshaw et al., 2004; Petko et al.,2005; Lenhard
`
`et al.,2005; Muller et al.,2004; Chen et al., 2005 and Lueng
`
`30
`
`et al., 2004).
`
`Geneoscopy Exhibit 1073, Page 6
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`-
`
`6 -
`
`Factors that may influence the sensitivity of the selected
`
`markers are sampling processing procedures and DNA isolation
`
`and extraction protocols. One challenge faced by
`
`researchers investigating colorectal cancer is the diversity
`
`5
`
`of DNA present in stool samples. Most of the DNA recovered
`
`from faecal samples is bacterial in origin, with the human
`
`DNA component representing only a very small minority. Human
`
`DNA from cells sloughed from the colonic mucosa represents
`
`as little as 0.1 to 0.01% of the total DNA recoverable from
`
`10
`
`stool. Additionally, the human DNA recovered is highly
`
`heterogeneous. Normal cells are sloughed into the colonic
`
`lumen along with only a small amount of tumour cells
`
`(approximately 1% of the cells sloughed). Thus, the DNA of
`
`interest represents only a very small percentage of the
`
`15
`
`total DNA isolated from stool. Therefore, along with the
`
`exploration of suitable DNA markers, techniques for improved
`
`DNA isolation and enrichment of the human DNA component from
`
`faecal samples have been developed for more sensitive cancer
`
`detection.
`
`20
`
`The initial DNA isolation techniques typically recovered DNA
`
`from 10g to 4g stool and more conveniently purified the
`
`human DNA component using streptavidin-bound magnetic beads
`
`(Dong et al., 2001; Ahlquist et al., 2000). Further
`
`25
`
`improvements in recovery of target human DNA from stool
`
`comprised an electrophoresis-driven separation of target DNA
`
`sequences, using oligonucleotide capture probes immobilized
`
`in an acrylamide gel (Whitney et al., 2004). Later, when DNA
`
`integrity proved to be a suitable marker it was also
`
`30
`
`important to prevent degradation during sample handling.
`
`Improved results were obtained with stool samples frozen as
`
`quickly as possible after collection. Alternatively,
`
`Geneoscopy Exhibit 1073, Page 7
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`-
`
`7 -
`
`stabilization buffer was added to the stool samples before
`
`further transport (Olson et al., 2005). A recent
`
`improvement involves the use of an MBD column to extract
`
`methylated human DNA in a high background of fecal bacterial
`
`5
`
`DNA
`
`(Zou et al., 2007). However, despite these advances,
`
`current tools for cancer detection in faecal samples are
`
`still unsatisfactory.
`
`Cancer at its early stage may release its cells or free DNA
`
`10
`
`into blood through apoptosis, necrosis or local
`
`angiogenesis, which establishes a basis for blood-based
`
`cancer testing. The usefulness of DNA methylation markers
`
`for detecting colorectal cancers in serum and plasma has
`
`been demonstrated (Grady et al., 2001, Leung et al., 2005;
`
`15 Nakayama et al., 2007). However, the potential use of serum
`
`and plasma for cancer detection is hampered by the limited
`
`level of methylated DNA present in the total DNA collected
`
`from plasma and serum samples (Zou et al. (2002) Clin Cancer
`
`Res 188-91). A further drawback is the partial degradation
`
`20
`
`of the methylated DNA due to bisulfite treatment, a
`
`treatment step required by many techniques that monitor DNA
`
`methylation.
`
`Methods and compositions for detection of early colorectal
`
`25
`
`cancer or pre-cancer using blood and body fluids have been
`
`described.
`
`WO 2006/113770 describes methods in which samples are pooled
`
`and concentrated in an attempt to maximize DNA input per
`
`30
`
`reaction. The initial processing of 45 ml of blood allowed
`
`a median DNA recovery of 3.86 ng/ml plasma. This was shown
`
`to result in a sensitivity of 57% and specificity of 96% for
`
`Geneoscopy Exhibit 1073, Page 8
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 8 -
`
`detection of colorectal cancer using a specific real-time
`
`assay for detecting whether The Septin 9 gene was
`
`methylated. Bisulphite treatment was focused on large
`
`volume treatment and achieving maximal conversion.
`
`5
`
`Lofton-Day et al. (AACR general meeting April 2007, Los
`
`Angeles, USA) mention improved detection of colorectal
`
`cancer, and obtained a 70% sensitivity and 90% specificity,
`
`with the same marker (Septin 9). The proposed method
`
`10 utilised four blood draws (40 ml blood), double
`
`centrifugation for plasma recovery and required four PCR
`
`reactions to be carried out for each sample tested. Three
`
`out of the four reactions used input DNA equivalent to 2 ml
`
`of plasma per PCR reaction. The fourth reaction used a 1/10
`
`15 dilution of this input DNA. Thus, repeated assays were
`
`required (at least 4) and an algorithm utilised to determine
`
`the final result. A sample was deemed positive if either
`
`two out of the three reactions with input DNA equivalent to
`
`2 ml of plasma, or the diluted measurement, were positive
`
`20
`
`for the Septin 9 assay. The improved sensitivity by using
`
`the diluted samples indicates the presence of inhibitors in
`
`the methods, a phenomena also described by Nakayama et al.
`
`(2007, Anticancer Res. 27(3B) :1459-63).
`
`25
`
`The processing of smaller amounts of blood have been
`
`described as well (US 20070141582, Hong-Zhi Zou et al. ,
`
`and Satoru Yamaguchi et al.) but all result in low level of
`
`methylated modified DNA detection.
`
`30 Thus, current blood-based screening methods lack
`
`sensitivity.
`
`Geneoscopy Exhibit 1073, Page 9
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 9 -
`
`SUMMARY OF THE INVENTION
`
`The invention, as set out in the claims, is based around the
`
`finding that NDRG4/2 subfamily genes, undergoe CpG island
`
`promoter methylation-associated gene silencing in human
`
`5
`
`cancer cells, in particular colon cancer cells. The
`
`hypermethylation of the NDRG family gene, such as NDRG4
`
`and/or NDRG2, in particular in the promoter region leads to
`
`its loss of expression. Importantly, the presence of
`
`aberrant methylation at the NDRG4/2 subfamily gene promoter
`
`10
`
`has a prognostic value. The epigenetic loss of NDRG4/2
`
`function can be rescued by the use of DNA demethylating
`
`agents and thus provides for a method for treatment. These
`
`findings underline the significance of the epigenetic
`
`silencing of the NDRG4/2 subfamily genes as one key step in
`
`15
`
`cancer development and may have an important clinical impact
`
`for the treatment of the patients.
`
`The present invention is also based upon the discovery of
`
`specific genes and panels of genes whose methylation status
`
`20
`
`is linked to the incidence of, or predisposition to,
`
`gastrointestinal cancers such as colorectal cancer. Use of
`
`these genes for detecting gastrointestinal cancers such as
`
`colorectal cancer, in particular in the context of
`
`appropriate tissue or faecal (stool) samples or of
`
`25
`
`appropriate blood samples (or derivatives thereof)
`
`respectively, has been shown to produce highly sensitive and
`
`specific results. The invention provides also for a method
`
`for isolating increased amount of DNA from faecal samples,
`
`which results in improved sensitivity of detection of
`
`30
`
`colorectal cancer in faecal samples.
`
`Geneoscopy Exhibit 1073, Page 10
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 10 -
`
`The invention also provides a method for determining the
`
`methylation status of a gene of interest in a blood based
`
`sample, which requires only low volumes of blood sample
`
`equivalent to generate specific and sensitive results. This
`
`5
`
`is advantageous since it permits smaller blood samples to be
`
`obtained from the subject under test.
`
`Accordingly, in a first aspect, the invention provides a
`
`method of detecting a predisposition to, or the incidence
`
`10
`
`of, cancer in a sample comprising detecting an epigenetic
`
`change in at least one gene selected from an NDRG4/NDRG2
`
`subfamily gene (in particular NDRG4), GATA4, OSMR, GATA5,
`
`SFRPl, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXEl,
`
`SYNEl, S0Xl7, PHACTR3 and JAM3, wherein detection of the
`
`15
`
`epigenetic change is indicative of a predisposition to, or
`
`the incidence of, cancer.
`
`Subsets of genes for all aspects and embodiments of the
`
`invention include an NDRG4/NDRG2 subfamily gene (in
`
`20 particular NDRG4), GATA4, OSMR, GATA5, SFRPl, ADAM23, JPH3,
`
`SFRP2, APC and MGMT and TFPI2, BNIP3, FOXEl, SYNEl, S0Xl7,
`
`PHACTR3 and JAM3 respectively. Each subset may be
`
`particularly applicable to bodily fluid samples, such as
`
`stool and plasma samples as discussed herein.
`
`25
`
`By "epigenetic change" is meant a modification in the gene
`
`caused by an epigenetic mechanism, such as a change in
`
`methylation status or histone acetylation for example.
`
`Frequently, the epigenetic change will result in an
`
`30
`
`alteration in the levels of expression of the gene which may
`
`be detected (at the RNA or protein level as appropriate) as
`
`an indication of the epigenetic change. Often the
`
`Geneoscopy Exhibit 1073, Page 11
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 11 -
`
`epigenetic change results in silencing or down regulation of
`
`the gene, referred to herein as "epigenetic silencing''. The
`
`most frequently investigated epigenetic change in the
`
`methods of the invention involves determining the
`
`5 methylation status of the gene, where an increased level of
`
`methylation is typically associated with the relevant cancer
`
`(since it may cause down regulation of gene expression).
`
`In a related aspect, the invention provides a method of
`
`10
`
`diagnosing cancer or predisposition to cancer comprising
`
`detecting epigenetic silencing of the NDRG4/NDRG2 subfamily
`
`gene, wherein epigenetic silencing of the gene is indicative
`
`for cancer or predisposition to cancer.
`
`15 The NDRG family genes have been characterised in the art
`
`(see, for example, Qu X et al., 2002 and references cited
`
`therein) and their epigenetic silencing can be assessed in
`
`terms of DNA methylation status or expression levels as
`
`determined by their methylation status.
`
`20
`
`In on~ embodiment, the invention provides for a method of
`
`diagnosing cancer or predisposition to cancer comprising
`
`detecting epigenetic silencing of the NDRG4/NDRG2 subfamily
`
`gene, wherein epigenetic silencing of the NDRG2/NDRG4-family
`
`25
`
`gene is detected by determination of the methylation status
`
`of the NDRG4/2 family gene and wherein methylation of the
`
`gene is indicative for cancer or predisposition to cancer.
`
`Since methylation of the NDRG4/NDRG2 subfamily gene
`
`30 manifests itself in reduced expression of the gene the
`
`invention also provides for a method of diagnosing cancer or
`
`predisposition to cancer comprising detecting epigenetic
`
`Geneoscopy Exhibit 1073, Page 12
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 12 -
`
`silencing of the NDRG4/NDRG2 subfamily gene, wherein
`
`epigenetic silencing of the NDRG2/NDRG4-family gene is
`
`determined by measurement of expression levels of the gene,
`
`wherein reduced expression of the gene is indicative for
`
`5
`
`cancer or predisposition to cancer.
`
`In a related aspect, the invention provides method of
`
`prognosis to cancer or predisposition to cancer comprising
`
`detecting epigenetic silencing of the NDRG4/NDRG2 subfamily
`
`10
`
`gene, wherein epigenetic silencing of the gene is indicative
`
`for cancer development or predisposition to cancer.
`
`Preferably, epigenetic silencing is detected by
`
`determination of the methylation status and/or measurement
`
`of expression levels of the NDRG2/NDRG4-family gene.
`
`15
`
`The invention also provides a method of detecting a
`
`predisposition to, or the incidence of, cancer and in
`
`particular a gastrointestinal cancer such as colorectal
`
`cancer in a sample comprising detecting an epigenetic change
`
`20
`
`in at least one gene selected from GATA4, OSMR, NDRG4,
`
`GATA5, SFRPl, ADAM23, JPH3, SFRP2, APC, and MGMT, and/or
`
`TFPI2, BNIP3, FOXEl, SYNEl, S0Xl7, PHACTR3 and JAM3, wherein
`
`detection of the epigenetic change is indicative of a
`
`predisposition to, or the incidence of, cancer and in
`
`25 particular a gastrointestinal cancer such as colorectal
`
`cancer. These subsets of genes may be particularly useful
`
`where faecal test samples are utilised (and plasma in
`
`certain embodiments).
`
`30
`
`In a related aspect, the invention also provides a method of
`
`detecting a predisposition to, or the incidence of, cancer
`
`and in particular a gastrointestinal cancer such as
`
`Geneoscopy Exhibit 1073, Page 13
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 13 -
`
`colorectal cancer in a sample and in particular in a blood
`
`sample, or derivative thereof comprising detecting an
`
`epigenetic change in at least one gene selected from GATA4,
`
`OSMR, NDRG4, GATA5, SFRPl, ADAM23, JPH3, SFRP2, APC, MGMT,
`
`5
`
`TFPI2, BNIP3, FOXEl, SYNEl, S0Xl7, PHACTR3 and JAM3(together
`
`with any suitable subset or panel thereof), wherein
`
`detection of the epigenetic change is indicative of a
`
`predisposition to, or the incidence of, cancer and in
`
`particular a gastrointestinal cancer such as colorectal
`
`10
`
`cancer.
`
`By "NDRG2/NDRG4 subfamily gene" is meant any gene which is
`
`taken from the subfamily to which NDRG4 and NDRG2 belong and
`
`includes according to all aspects of the invention NDRG2 and
`
`15 NDRG4. Note that "NDRGl, NDRG2, NDRG3 and NDRG4" is the
`
`standard nomenclature approved by the human genome
`
`organisation for the NDRG family genes, to ensure that each
`
`symbol is unique. The listed accession number for these
`
`genes can be found at www.gene.ucl.ac.uk/nomenclature.
`
`20
`
`NDRG family genes encompass not only the particular
`
`sequences found in the publicly available database entries,
`
`but also encompass transcript variants of these sequences.
`
`Variant forms of the encoded proteins may comprise post-
`
`25
`
`translational modification, may result from spliced
`
`messages, etc.... NDRG4 has transcript variants having the
`
`accession numbers NM 020465 and NM 022910. NDRG2 has
`
`several transcript variants having the accession numbers,
`
`NM_201535, NM_201536, NM_201537, NM_201538, NM_201539,
`
`30 NM_201540, NM 2015401 and NM 016250. Variant sequences may
`
`have at least 90%, at least 91%, at least 92%, at least 93%,
`
`at least 94%, at least 95%, at least 96%, at least 97%, at
`
`Geneoscopy Exhibit 1073, Page 14
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 14 -
`
`least 98%, or at least 99% identity to sequences in the
`
`database entries or sequence listing. Computer programs for
`
`determining percent identity are available in the art,
`
`including Basic Local Alignment Search Tool (BLASTS)
`
`5
`
`available from the National Center for Biotechnology
`
`Information.
`
`GATA4 is the gene symbol approved by the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 8
`
`10
`
`(location p23.1-p22) and the gene sequence is listed under
`
`the accession numbers AK097060, NM_002052 and
`
`ENSG00000136574. The gene encodes GATA binding protein 4.
`
`OSMR is the gene symbol approved by the HUGO Gene
`
`15 Nomenclature Committee. The gene is located on chromosome 5
`
`(location p13.2) and the gene sequence is listed under the
`
`accession numbers U60805, NM 003999 and ENSG00000145623. The
`
`gene encodes oncostatin M receptor.
`
`20
`
`NDRG4 is the gene symbol approved by the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 16
`
`(location q21-q22.3) and the gene sequence is listed under
`
`the accession numbers AB044947 and ENSG00000103034. The gene
`
`encodes NDRG family member 4.
`
`25
`
`30
`
`GATA5 is the gene symbol approved by the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 20
`
`and the gene sequence is listed under the accession number
`
`ENSG00000130700. The gene encodes GATA binding protein 5.
`
`SFRPl is the gene symbol approved by the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 8
`
`Geneoscopy Exhibit 1073, Page 15
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 15 -
`
`(location pll.21) and the gene sequence is listed under the
`
`accession numbers AF017987, NM_003012 and ENSG00000104332.
`
`The gene encodes secreted frizzled-related protein 1.
`
`5 ADAM23 is the gene symbol approved by the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 2
`
`(location q33) and the gene sequence is listed under the
`
`accession numbers AB009672 and ENSG00000114948. The gene
`
`encodes ADAM metallopeptidase domain 23.
`
`10
`
`JPH3 is the gene symbol approved by the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 16
`
`(location q24.3) and the gene sequence is listed under the
`
`accession numbers AB042636 and ENSG00000154118. The gene
`
`15
`
`encodes junctophilin 3.
`
`SFRP2 is the gene symbol approved by the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 4
`
`(location q31.3) and the gene sequence is listed under the
`
`20
`
`accession numbers AF017986 and ENSG00000145423. The gene
`
`encodes secreted frizzled-related protein 2.
`
`APC is the gene symbol approved by the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 5
`
`25
`
`(location q21-q22) and the gene sequence is listed under the
`
`accession numbers M74088 and ENSG00000134982. The gene
`
`encodes adenomatosis polyposis coli.
`
`The MGMT gene encodes 06-methylguanine-DNA methyltransferase
`
`30
`
`(MGMT), which is a cellular DNA repair protein that rapidly
`
`reverses alkylation (e.g. methylation) at the 06 position of
`
`guanine, thereby neutralizing the cytotoxic effects of
`
`Geneoscopy Exhibit 1073, Page 16
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 16 -
`
`alkylating agents such as temozolomide (TMZ) and carmustine
`
`(1-3). MGMT is the gene symbol approved by the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome
`
`10 (location 10q26) and the gene sequence is listed under
`
`5
`
`the accession numbers M29971, NM 002412 and ENSG00000170430.
`
`BNIP3
`
`is
`
`the gene
`
`symbol
`
`approved by
`
`the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 10
`
`(location 10q26.3) and the gene sequence is listed under the
`
`10
`
`accession numbers Ul5174
`
`and ENSG00000176171. The gene
`
`encodes the BCL2/adenovirus ElB 19kDa interacting protein 3.
`
`FOXEl
`
`is
`
`the gene
`
`symbol
`
`approved by
`
`the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 9
`
`15
`
`( location 9q22) and the gene sequence is listed under the
`
`accession numbers U89995
`
`and ENSG00000178919. The gene
`
`encodes the forkhead box El (thyroid transcription factor 2)
`
`JAM3
`
`is
`
`the gene
`
`symbol
`
`approved by
`
`the HUGO Gene
`
`20 Nomenclature Committee. The gene is located on chromosome 11
`
`(location llq25) and the gene sequence is listed under the
`
`accession numbers AF356518, NM 032801 and ENSG00000166086.
`
`The gene encodes the junctional adhesion molecule 3.
`
`25
`
`PHACTR3
`
`is
`
`the gene
`
`symbol approved by
`
`the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 20
`
`(location 20ql3. 32) and the gene sequence is listed under
`
`30
`
`the
`
`accession
`
`numbers
`
`AJ311122,
`
`NM 080672
`
`and
`
`ENSG00000087495. The gene encodes the phosphatase and actin
`
`regulator 3.
`
`Geneoscopy Exhibit 1073, Page 17
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 17 -
`
`TFPI2
`
`is
`
`the gene
`
`symbol
`
`approved by
`
`the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 7
`
`(location 7q22) and the gene sequence is listed under· the
`
`5
`
`accession numbers L27624
`
`and ENSG00000105825. The gene
`
`encodes the tissue factor pathway inhibitor 2.
`
`SOX17
`
`is
`
`the gene
`
`symbol
`
`approved by
`
`the HUGO Gene
`
`Nomenclature Committee. The gene is located on chromosome 8
`
`10
`
`(location Bqll.23) and the gene sequence is listed under the
`
`accession numbers AB073988 and ENSG00000164736. The gene
`
`encodes the SRY (sex determining region Y)-box 17.
`
`SYNEl
`
`is
`
`the gene
`
`symbol
`
`approved by
`
`the HUGO Gene
`
`15 Nomenclature Committee. The gene is located on chromosome 6
`
`(location 6q25) and the gene sequence is listed under the
`
`accession numbers AB018339 and ENSG00000131018. The gene
`
`encodes the spectrin repeat containing, nuclear envelope 1.
`
`20 Of course, as appropriate, the skilled person would
`
`appreciate that functionally relevant variants of each of
`
`the gene sequences may also be detected according to the
`
`methods of the invention. For example, the methylation
`
`status of a number of splice variants may be determined
`
`25
`
`according to the methods of the invention. Variant
`
`sequences preferably have at least 90%, at least 91%, at
`
`least 92%, at least 93%, at least 94%, at least 95%, at
`
`least 96%, at least 97%, at least 98%, or at least 99%
`
`nucleotide sequence identity with the nucleotide sequences
`
`30
`
`in the database entries. Computer programs for determining
`
`percentage nucleotide sequence identity are available in the
`
`art, including the Basic Local Alignment Search Tool (BLAST)
`
`Geneoscopy Exhibit 1073, Page 18
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 18 -
`
`available from the National Center for Biotechnology
`
`Information.
`
`The methods of the invention are generally ex vivo or in
`
`5
`
`vitro methods carried out on a test sample, in particular on
`
`an isolated test sample. The methods can be used to
`
`diagnose any suitable type of cancer. The cancer comprises,
`
`consists essentially of or consists of a neoplasia of the
`
`gastrointestinal tract such as gastrointestinal cancer in
`
`10
`
`one embodiment.
`
`In specific embodiments, the methods of the
`
`invention are applied to colorectal cancer, gastric cancer
`
`and/or oesophageal cancer.
`
`In more specific embodiments,
`
`the methods are used to diagnose colorectal cancer, and more
`
`particularly to diagnose hereditary nonpolyposis colon
`
`15
`
`cancer and/or sporadic colorectal cancer. Alternatively, the
`
`methods are aimed at diagnosis of gastric cancer.
`
`Preferably, the methods are used to diagnose colorectal
`
`cancer and/or gastric cancer. The methods may be used to
`
`detect carcinoma or adenoma, in particular advanced adenoma.
`
`20
`
`The methods may be employed in the diagnosis of both diffuse
`
`type and intestinal type carcinomas of the stomach,
`
`particularly when the methylation status of NDRG4 is
`
`determined.
`
`In one embodiment the methods may also include
`
`the step of obtaining the sample.
`
`25
`
`In one specific embodiment, the methods are used to diagnose
`
`oesophageal adenocarcinoma.
`
`In particular, the methylation
`
`status of the NDRG4 gene (promoter) has been shown for the
`
`first time herein to be linked with high sensitivity and
`
`30
`
`specificity to the incidence of this particular cancer type.
`
`Oesophageal adenocarcinoma may be distinguished from
`
`oesophageal squamous cell carcinomas on this basis.
`
`Geneoscopy Exhibit 1073, Page 19
`
`
`
`WO 2008/084219
`
`PCT/GB2008/000056
`
`- 19 -
`
`The "test sample" can be any tissue sample or body fluid.
`
`Preferably, the test sample is obtained from a human
`
`subject.
`
`In specific embodiments, the sample is taken from
`
`5
`
`the gastrointestinal tract. The sample may be a colorectal
`
`tissue sample or a colon, rectal, oesophageal, stomach or
`
`appendix tissue sample or a faecal or blood based sample
`
`from a subject. For faecal samples the methods are
`
`preferably used with respect to detecting gastrointestinal
`
`10
`
`cancers such as colorectal cancer as discussed herein, but
`
`may also be useful in identifying potentially dangerous
`
`adenomas. Different markers and panels of markers may be
`
`most useful with a specific sample type, such as a tissue,
`
`blood based or faecal sample as discussed herein in detail.
`
`15
`
`Thus, for example, in one embodiment, the methods of the
`
`invention involve detecting an epigenetic change, and in
`
`particular determining the methylation status, of (at least)
`
`the NDRG4 gene in a faecal test sample, wherein detection of
`
`20
`
`the epigenetic change, in particular (hyper)methylation of
`
`the NDRG4 gene (promoter) is indicative of gastrointestinal
`
`neoplasias/cancer, in particular colorectal cancer, such as
`
`adenomas and carcinomas, gastric cancer and other
`
`adenocarcinomas of the gastrointestinal tract (such as
`
`25
`
`oesophageal adenocarcinoma) and/or diffuse type and
`
`intestinal type carcinomas of the stomach.
`
`The subject may be suspected of being tumorigenic. More
`
`specifically the subject ma
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
